Board of Directors
Ms. Shah has a 17-year track record of leadership and management in the biopharmaceutical industry, as well as in investment banking, with particular experience in financial strategy, capital markets and business development. She previously held the role of chief business and financial officer at rare disease company ProQR, joining as chief financial officer in 2014. Previously, Ms. Shah managed the multi-billion-dollar debt, cash and investment portfolios of Gilead Sciences. Prior to Gilead, she was an investment banker at Leerink Partners and JP Morgan where she helped raise over $1 billion in equity capital and over $7 billion in debt capital for emerging and established biotech companies and advised on M&A. Previously, Ms. Shah held various R&D roles at Johnson & Johnson. She earned both bachelor’s and master’s degrees in chemical engineering and an MBA from the University of California at Berkeley.